Showing results (181-190 of 192) with videos related to
Sort By:
Pageof 20
Proceedings of the National Academy of Sciences of the United States of America|July 7, 2025
Common inherited loss-of-function mutations in the innate sensor NOD2 contribute to exceptional immune response to cancer immunotherapyMegan B Barnet, Katherine J L Jackson, Etienne Masle-Farquhar, et al.Lancet (London, England)|February 14, 2021
[<sup>177</sup>Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trialMichael S Hofman, Louise Emmett, Shahneen Sandhu, et al.European Urology Oncology|February 3, 2026
Radiographic Progression Without Prostate-specific Antigen Progression in Metastatic Hormone-sensitive Prostate Cancer: A Retrospective Analysis of the ENZAMET Trial (ANZUP 1304)Andrisha-Jade Inderjeeth, Andrew J Martin, Robert R Zielinski, et al.Radiology|April 28, 2026
<sup>177</sup>Lu-PSMA-617 SPECT/CT for Early Prediction of Overall Survival in Participants with Metastatic Castration-Resistant Prostate CancerNarjess Ayati, Nathan Papa, Megan Crumbaker, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 20, 2021
Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUPMartin R Stockler, Andrew J Martin, Ian D Davis, et al.The Lancet. Oncology|April 15, 2024
[<sup>177</sup>Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trialLouise Emmett, Shalini Subramaniam, Megan Crumbaker, et al.The Lancet. Oncology|February 16, 2025
Overall survival and quality of life with [<sup>177</sup>Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trialLouise Emmett, Shalini Subramaniam, Megan Crumbaker, et al.Science Advances|May 1, 2023
Monitoring AKT activity and targeting in live tissue and disease contexts using a real-time Akt-FRET biosensor mouseJames R W Conway, Sean C Warren, Young-Kyung Lee, et al.Cancer Immunology, Immunotherapy : CII|February 13, 2019
Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2Linh T Nguyen, Samuel D Saibil, Valentin Sotov, et al.Science Advances|March 12, 2025
Targeting the NPY/NPY1R signaling axis in mutant p53-dependent pancreatic cancer impairs metastasisCecilia R Chambers, Supitchaya Watakul, Peter Schofield, et al.Pageof 20